Sugi Predict

Sugi Predict / Compounds / SCHEMBL2996065

SCHEMBL2996065

SCHEMBL2996065

COc1cc2c(nc1OC)c(-c1cc3c(C=O)ccnc3n1S(=O)(=O)c1ccc(C)cc1)cn2C

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.33
▸ UBE2N P61088 1/20 0.33
▸ MET P08581 1/20 0.33
▸ AXL P30530 1/20 0.33
▸ PTGDR2 Q9Y5Y4 4/20 0.32
▸ PIM1 P11309 1/20 0.31
▸ PIM2 Q9P1W9 1/20 0.31
▸ LMNA P02545 3/20 0.31
▸ IGF1R P08069 1/20 0.31
▸ PCSK9 Q8NBP7 1/20 0.31
▸ ALDH1A1 P00352 3/20 0.31
▸ ALDH3A1 P30838 2/20 0.31
▸ TP53 P04637 2/20 0.30
▸ MAPT P10636 2/20 0.30
▸ SMN1; SMN2 Q16637 2/20 0.30
▸ TSHR P16473 2/20 0.30
▸ HPGD P15428 1/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2984672 0.91 GFER (0.33) METAXLPTGDR2PIM1PIM2
SCHEMBL2984670 0.91 GFER (0.33) METAXLPTGDR2PIM1PIM2
SCHEMBL2990286 0.89 PTGDR2 (0.39) KDM4EMETAXLPTGDR2PIM1
SCHEMBL3000511 0.89 LMNA (0.37) KDM4EMETAXLPTGDR2PIM1
SCHEMBL1748958 0.88 IGF1R (0.38) KDM4EUBE2NMETAXLPTGDR2
SCHEMBL2989018 0.86 PCSK9 (0.34) METAXLPTGDR2PIM1PIM2
SCHEMBL2995941 0.86 PTGDR2 (0.36) METAXLPTGDR2PIM1PIM2
SCHEMBL2991313 0.86 PCSK9 (0.34) KDM4EMETAXLPTGDR2PIM1
SCHEMBL15085748 0.84 PCSK9 (0.34) KDM4EPTGDR2PIM1PIM2LMNA
SCHEMBL13093819 0.84 L3MBTL1 (0.42) KDM4EPTGDR2LMNAIGF1RPCSK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799691-B1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2011-12-21 — — EP disclosed
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2010-10-07 — — US disclosed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 — — US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors BRSK2, KSR2, CDK2 KDM4E 772/4885UBE2N 2907/4885MET 1028/4885
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS BRSK2, KSR2, CDK2 KDM4E 772/4885UBE2N 2907/4885MET 1028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.